CXCL9 and neoplasm: CXCL9(86-103) could not significantly improve diabetes-induced vascular leakage and had also no anti-angiogenic activity in several in vivo models, including tumor-associated angiogenesis and FGF-2-induced angiogenesis in the Matrigel plug assay (data not shown).